Select Publications

Journal articles

Brzozowska MM; Isaacs M; Bliuc D; Baldock PA; Eisman JA; White CP; Greenfield JR; Center JR, 2023, 'Effects of bariatric surgery and dietary intervention on insulin resistance and appetite hormones over a 3 year period', Scientific Reports, 13, pp. 6032,

Sheu A; Blank RD; Tran T; Bliuc D; Greenfield JR; White CP; Center JR, 2023, 'Associations of Type 2 Diabetes, Body Composition, and Insulin Resistance with Bone Parameters: The Dubbo Osteoporosis Epidemiology Study', JBMR Plus, 7,

Lin J; Pearson SA; Greenfield JR; Park KH; Havard A; Brieger D; Day RO; Falster MO; de Oliveira Costa J, 2023, 'Trends in use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in Australia in the era of increased evidence of their cardiovascular benefits (2014–2022)', European Journal of Clinical Pharmacology, 79, pp. 1239 - 1248,

Raven LM; Stoita A; Feller RB; Brown C; Greenfield JR, 2023, 'Delayed gastric emptying with perioperative use of glucagon-like peptide-1 receptor agonists.', Am J Med,

Chowdhury G; Carland JE; Kumar S; Olsen N; Graham G; Kumarasinghe G; Hayward CS; Greenfield JR; Macdonald P; Day RO; Stocker SL, 2023, 'The safe use of metformin in heart failure patients both with and without T2DM: A cross-sectional and longitudinal study', British Journal of Clinical Pharmacology, 89, pp. 2603 - 2613,

RAVEN LM; MUIR CA; POULIOPOULOS JIM; MACDONALD PS; JABBOUR A; GREENFIELD J, 2023, '1438-P: Diabetes after Cardiac Transplant with Low-Dose Everolimus and Tacrolimus', Diabetes, 72,

Lasschuit JWJ; Greenfield JR; Tonks KTT, 2023, 'Response to the Letter to the Editor regarding “Contribution of peripheral neuropathy to poor bone health in the feet of people with type 2 diabetes mellitus”', Acta Diabetologica, 60, pp. 713 - 714,

Raven LM; Muir CA; Macdonald PS; Hayward CS; Jabbour A; Greenfield JR, 2023, 'Diabetes medication following heart transplantation: a focus on novel cardioprotective therapies—a joint review from endocrinologists and cardiologists', Acta Diabetologica, 60, pp. 471 - 480,

Chavali S; Barua S; Adjii A; Robson D; Raven L; Greenfield J; Parvar S; MacDonald P; Hayward C; Muthiah K, 2023, 'Safety and Tolerability of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Patients Supported with Left Ventricular Assist Devices', JOURNAL OF HEART AND LUNG TRANSPLANTATION, 42, pp. S450 - S451,

Raven LM; Muir CA; Kessler Iglesias C; Bart NK; Muthiah K; Kotlyar E; Macdonald P; Hayward CS; Jabbour A; Greenfield JR, 2023, 'Sodium glucose co-transporter 2 inhibition with empagliflozin on metabolic, cardiac and renal outcomes in recent cardiac transplant recipients (EMPA-HTx): Protocol for a randomised controlled trial', BMJ Open, 13, pp. e069641,

Cooper B; Blaker K; Greenfield JR, 2023, 'Olanzapine-induced multifactorial chylomicronaemia syndrome: a rare but important complication', ENDOCRINOLOGY DIABETES AND METABOLISM CASE REPORTS, 2023,

Milder TY; Stocker SL; Baysari MT; Day RO; Greenfield JR, 2023, '‘We are somehow fixated on this being a diabetes drug’: a qualitative study exploring the views of cardiologists and nephrologists about sodium-glucose cotransporter 2 inhibitor initiation', Internal Medicine Journal,

Sheu A; Greenfield JR; White CP; Center JR, 2023, 'Contributors to impaired bone health in type 2 diabetes', Trends in Endocrinology and Metabolism, 34, pp. 34 - 48,

Raven LM; Muir CA; Pouliopoulos J; Hayward CS; Macdonald PS; Greenfield JR; Jabbour A, 2023, 'Metabolic Sequelae of Everolimus Treatment After Cardiac Transplant: A Hypothesis-Generating Study', Heart Lung and Circulation,

Snaith JR; Greenfield JR; Malozowski S; Weghuber D; Kelly AS; Arslanian S, 2023, 'Once-Weekly Semaglutide in Adolescents with Obesity', New England Journal of Medicine, 388, pp. 1145,

Milder TY; Greenfield JR; Milder DA, 2023, 'Peri-procedural ketoacidosis risk with sodium-glucose cotransporter 2 inhibitor use in people without diabetes', Anaesthesia,

Chavali S; Barua S; Adji A; Robson D; Raven LM; Greenfield JR; Eckford H; Macdonald PS; Hayward CS; Muthiah K, 2023, 'Safety and tolerability of sodium-glucose cotransporter-2 inhibitors in bridge-to-transplant patients supported with centrifugal-flow left ventricular assist devices', International Journal of Cardiology, pp. 131259,

Raven LM; Muir CA; Greenfield JR, 2023, 'Sodium glucose cotransporter 2 inhibitor-induced ketoacidosis is unlikely in patients without diabetes', Medical Journal of Australia,

Koay YC; Coster ACF; Chen DL; Milner B; Batarseh A; O’Sullivan JF; Greenfield JR; Samocha-Bonet D, 2022, 'Metabolomics and Lipidomics Signatures of Insulin Resistance and Abdominal Fat Depots in People Living with Obesity', Metabolites, 12,

Raven LM; Greenfield JR; Muir CA, 2022, 'Glucagon-like Peptide-1 Receptor Agonist Treatment With Semaglutide in Type 1 Diabetes', JCEM Case Reports, 1,

Moxham R; Greenfield JR; Viardot A; Wu KHC, 2022, 'Tip of the iceberg: are we missing undiagnosed patients with maturity onset diabetes of the young?', Internal Medicine Journal, 52, pp. 2011 - 2012,

Patel SK; Ma CS; Bell KJ; Oram R; Hagopian WA; Fourlanos S; Greenfield JR, 2022, 'Immunophenotype and genetic risk scores to improve autoantibody negative type 1 diabetes classification: study protocol', International Journal of Clinical Trials, 9, pp. 293 - 293,

Tiwary M; Milder TY; Stocker SL; Day RO; Greenfield JR, 2022, 'Sodium-glucose co-transporter 2 inhibitor therapy: use in chronic kidney disease and adjunctive sodium restriction', Internal Medicine Journal, 52, pp. 1666 - 1676,

Raven LM; Morris P; Greenfield JR, 2022, 'Hyperglycaemia induced by gamma-butyrolactone', Diabetic Medicine, 39, pp. e14850,

Snaith JR; Greenfield JR, 2022, 'Sodium–glucose cotransporter 2 inhibitors in type 1 diabetes: a missed opportunity for cardiovascular protection?', Medical Journal of Australia, 217, pp. 126 - 128,

Brzozowska M; Isaacs M; Bliuc D; Baldock P; Eisman J; White C; Greenfield J; Center J, 2022, 'Effects of bariatric surgery and dietary intervention on changes in insulin resistance and appetite hormones over the period of 3 years', Endocrine Abstracts,

Sheu A; Greenfield JR; White CP; Center JR, 2022, 'Assessment and treatment of osteoporosis and fractures in type 2 diabetes', Trends in Endocrinology and Metabolism, 33, pp. 333 - 344,

Raven LM; Mccormack AI; Greenfield JR, 2022, 'Letter to the Editor From Raven et al: "Three Cases of Subacute Thyroiditis Following SARS-CoV-2 Vaccine"', Journal of Clinical Endocrinology and Metabolism, 107, pp. E1767 - E1768,

Lasschuit JWJ; Greenfield JR; Tonks KTT, 2022, 'Contribution of peripheral neuropathy to poor bone health in the feet of people with type 2 diabetes mellitus', Acta Diabetologica, 59, pp. 217 - 224,

Bennett MJ; Balcerek MI; Lewis EAD; Zhang RLL; Bachmeier C; Tey S; Faux S; Girgis L; Greenfield JR; Lazarus S, 2022, 'Voriconazole-Associated Periostitis: New Insights into Pathophysiology and Management', JBMR Plus, 6,

Dahiya S; Tisch S; Greenfield J, 2022, 'The effect of GLP-1 receptor agonists in pre-clinical rodent models of Parkinson's disease: A systematic review and meta-analysis', Clinical Parkinsonism and Related Disorders, 6,

Milder T; Stocker S; Baysari M; Day R; Greenfield J, 2022, 'Prescribing of SGLT2 Inhibitors in Clinical Practice: A Qualitative Study of Cardiologists', Heart, Lung and Circulation, 31, pp. S96 - S97,

Chavali S; Muthiah K; Hayward C; Macdonald P; Robson D; Greenfield J; Raven L, 2022, 'Safety and Tolerability of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Patients Supported With Left Ventricular Assist Devices', Heart, Lung and Circulation, 31, pp. S100 - S100,

Snaith JR; Danta M; Greenfield JR, 2021, 'Metabolic dysfunction-associated fatty liver disease and insulin resistance in type 1 diabetes', The Lancet Gastroenterology and Hepatology, 6, pp. 985 - 986,

Watt KI; Henstridge DC; Ziemann M; Sim CB; Montgomery MK; Samocha-Bonet D; Parker BL; Dodd GT; Bond ST; Salmi TM; Lee RS; Thomson RE; Hagg A; Davey JR; Qian H; Koopman R; El-Osta A; Greenfield JR; Watt MJ; Febbraio MA; Drew BG; Cox AG; Porrello ER; Harvey KF; Gregorevic P, 2021, 'Yap regulates skeletal muscle fatty acid oxidation and adiposity in metabolic disease', Nature Communications, 12, pp. 2887,

Milder TY; Stocker SL; Baysari M; Day RO; Greenfield JR, 2021, 'Prescribing of SGLT2 inhibitors in primary care: A qualitative study of General Practitioners and Endocrinologists', Diabetes Research and Clinical Practice, 180, pp. 109036,

Perera CJ; Falasca M; Chari ST; Greenfield JR; Xu Z; Pirola RC; Wilson JS; Apte MV, 2021, 'Role of pancreatic stellate cell-derived exosomes in pancreatic cancer-related diabetes: A novel hypothesis', Cancers, 13,

Heidegger DP; Neal KE; Patel SK; Greenfield JR; Tonks KT, 2021, 'Effect of fasting ketosis and type 1 diabetes on alcohol breath analysis technology used in Australia', Internal Medicine Journal, 51, pp. 1555 - 1556,

Snaith JR; Samocha-Bonet D; Evans J; Liu Z; Kowalski G; Bruce C; Holmes-Walker DJ; Greenfield JR, 2021, 'Insulin resistance in type 1 diabetes managed with metformin (INTIMET): Study protocol of a double-blind placebo-controlled, randomised trial', Diabetic Medicine, 38, pp. e14564,

Milder T; Stocker S; Baysari M; Day RO; Greenfield J, 2021, 'Prescribing of SGLT2 Inhibitors in Primary Care: A Qualitative Study of Primary Care Physicians and Endocrinologists', DIABETES, 70,

Patel SK; Ma CS; Fourlanos S; Greenfield JR, 2021, 'Autoantibody-Negative Type 1 Diabetes: A Neglected Subtype', Trends in Endocrinology and Metabolism, 32, pp. 295 - 305,

Patel SK; Fourlanos S; Greenfield JR, 2021, 'Comment on ‘impact of routine Clinic Measurement of random Serum c-peptide in people with a Clinician Diagnosis of type 1 diabetes’', Diabetic Medicine, 38, pp. e14513,

Bishay RH; Tonks KT; George J; Samocha-Bonet D; Meyerowitz-Katz G; Chisholm DJ; James DE; Greenfield JR, 2021, 'Plasma Bile Acids More Closely Align with Insulin Resistance, Visceral and Hepatic Adiposity Than Total Adiposity', Journal of Clinical Endocrinology and Metabolism, 106, pp. E1131 - E1139,

Milder TY; Stocker SL; Day RO; Greenfield JR, 2020, 'Potential Safety Issues with Use of Sodium-Glucose Cotransporter 2 Inhibitors, Particularly in People with Type 2 Diabetes and Chronic Kidney Disease', Drug Safety, 43, pp. 1211 - 1221,

Lasschuit JWJ; Center JR; Greenfield JR; Tonks KTT, 2020, 'Comparison of calcaneal quantitative ultrasound and bone densitometry parameters as fracture risk predictors in type 2 diabetes mellitus', Diabetic Medicine, 37, pp. 1902 - 1909,

Htet TD; Godneva A; Liu Z; Chalmers E; Kolobkov D; Snaith JR; Richens R; Toth K; Danta M; Hng TM; Elinav E; Segal E; Greenfield JR; Samocha-Bonet D, 2020, 'Rationale and design of a randomised controlled trial testing the effect of personalised diet in individuals with pre-diabetes or type 2 diabetes mellitus treated with metformin', BMJ Open, 10, pp. e037859,

Snaith JR; Holmes-Walker DJ; Greenfield JR, 2020, 'Letter to the editor: ⇜risk factors for cardiovascular disease (CVD) in adults with type 1 diabetes: findings from prospective real-life T1D exchange registry”', Journal of Clinical Endocrinology and Metabolism, 105, pp. 1 - 2,

Hussain I; Jin RR; Baum HBA; Greenfield JR; Devery S; Xing C; Hegele RA; Carranza-Leon BG; Linton MF; Vuitch F; Wu KHC; Precioso DR; Oshima J; Agarwal AK; Garg A, 2020, 'Multisystem progeroid syndrome with lipodystrophy, cardiomyopathy, and nephropathy due to an LMNA p.R349W variant', Journal of the Endocrine Society, 4,

Martin C; Ait Boudaoud A; Poghosyan T; Zhu J; Larger E; Greenfield JR; Czernichow S; Rives-Lange C; Carette C, 2020, 'Prevalence of anti-GAD and IA2 autoantibodies in a French cohort of patients with diabetes eligible for bariatric surgery', Diabetes and Metabolism, 46, pp. 407 - 409,

Snaith JR; Greenfield JR, 2020, 'COVID-19: it's changed us', Internal Medicine Journal, 50, pp. 1162 - 1163,

Back to profile page